The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001017314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/07/2026
Date registered
Help: Date registered
18/08/2026
Date last updated
Help: Date last updated
18/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
18/08/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
An Open Label Study of Alcohol Withdrawal Syndrome in the Outpatient Setting Using Vigabatrin
Scientific title
An Open Label Prospective Study of the Safety and Tolerability of Outpatient Treatment of Alcohol Withdrawal Syndrome Using the Gamma-Aminobutyric Acid Transaminase Inhibitor Vigabatrin
Additional trial identifiers [1] 317993 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Alcohol Withdrawal Syndrome 342989 0
Condition category
Condition code
Mental Health 339091 339091 0 0
Addiction

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Drug: Vigabatrin
Dose: 2g daily
Duration: 4 days
Delivery: Oral Tablet
Adherence: Monitoring via patient self-report or visual monitoring during in-person clinical interview
Intervention code [1] 334873 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346332 0
• Number of participants completing home based withdrawal. This will be assessed as a composite outcome.
Timepoint [1] 346332 0
Alcohol free days will be assessed at the end of 7 days post commencement of interventiion. CIWA-Ar, Urinary ethyl glucuronide (EtG) and breath alcohol concentration (BAC) will be assessed at baseline and at 2, 4, and 7 days post commencement of intervention
Primary outcome [2] 346333 0
• Total diazepam dose
Timepoint [2] 346333 0
Assessed at 2, 4, and 7 days post commencement of intervention
Secondary outcome [1] 465431 0
• Adherence to vigabatrin
Timepoint [1] 465431 0
Days 1 - 4 post commencement of intervention
Secondary outcome [2] 465432 0
• Abstinence from alcohol. This will be assessed as a composite outcome.
Timepoint [2] 465432 0
Days 2, 4, 7 post-commencement of intervention
Secondary outcome [3] 465433 0
alcohol use
Timepoint [3] 465433 0
30 days post cessation of trial medication (Day 4)
Secondary outcome [4] 465434 0
Number of patients that discontinued home based treatment
Timepoint [4] 465434 0
7 days post commencement of intervention
Secondary outcome [5] 465435 0
Safety Parameters
Timepoint [5] 465435 0
Days 2, 4, andd 7 post commencement of intervention. 30 days post-cessation of trial medication
Secondary outcome [6] 465759 0
Other substance Use
Timepoint [6] 465759 0
30 days post cessation of trial medication (Day 4)

Eligibility
Key inclusion criteria
1. Previous diagnosis of Alcohol Withdrawal Syndrome (AWS) upon cessation of alcohol.
2. Independent in their activities of daily living
3. Stable housing, with the capacity to reside with a support person for the duration of the study.
4. Able to attend in-person consultations at the outpatient clinic,
5. Capable of taking oral medication, and
6. Has not received treatment for AWS within the seven days prior to enrollment.
7. Able and willing to provide informed consent to participate in the study
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Current polysubstance use: except caffeine, nicotine
2. Past history of severe symptoms e.g., alcohol withdrawal seizures or delirium tremens
3. Major psychiatric disorders, eg: psychotic disorder, bipolar affective disorder, actively suicidal
4. Unable to consent to trial
5. Acute or unstable medical disorders: acute pancreatitis within 3 months; exercise tolerance less than 100 meters (>4 Metalbolic Equivalent of Tasks [METS] walk up flight of stairs); unstable cardiovascular diseases: unstable angina, myocardial infarction within the last 6 months, episode of syncope within the last 6 months; severe hepatic dysfunction (Child-Pugh B or C cirrhosis); Insulin-requiring Diabetes Mellitus; seizure disorders
6. Pregnant (urine ßHCG positive) or breast feeding
7. Known sensitivity to vigabatrin
8. Already receiving vigabatrin, benzodiazepines, baclofen, GABApentanoids, anti-epileptic drugs (AEDs)
9. Assessed by clinicians for other reasons not specified above as not suitable for the trial, including visual field defects.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The sample size of 50 is based on the number of participants likely to be recruited over a 12 month period.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29898 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment postcode(s) [1] 46256 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 322542 0
Hospital
Name [1] 322542 0
St Vincent's Hospital Melbourne Research Endowment Fund
Country [1] 322542 0
Australia
Primary sponsor type
Hospital
Name
St Vincents Hospital Melbourne
Address
Country
Australia
Secondary sponsor category [1] 325464 0
None
Name [1] 325464 0
Address [1] 325464 0
Country [1] 325464 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321024 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 321024 0
Ethics committee country [1] 321024 0
Australia
Date submitted for ethics approval [1] 321024 0
23/06/2025
Approval date [1] 321024 0
25/02/2026
Ethics approval number [1] 321024 0
215/25

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152406 0
Ms Cenyi Ai
Address 152406 0
Department of Addiction Medicine, St Vincent's Hospital Melbourne, 62 Gertrude St, Fitzroy, Victoria 3065
Country 152406 0
Australia
Phone 152406 0
+61 3 92316945
Fax 152406 0
Email 152406 0
Contact person for public queries
Name 152407 0
Amanda Norman
Address 152407 0
Department of Addiction Medicine, St Vincent's Hospital Melbourne, 62 Gertrude St, Fitzroy, Victoria 3065
Country 152407 0
Australia
Phone 152407 0
+61 3 92316947
Fax 152407 0
Email 152407 0
Contact person for scientific queries
Name 152408 0
Yvonne Bonomo
Address 152408 0
Department of Addiction Medicine, St Vincent's Hospital Melbourne, 62 Gertrude St, Fitzroy, Victoria 3065
Country 152408 0
Australia
Phone 152408 0
+61 3 92316991
Fax 152408 0
Email 152408 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.